Dr. Christian Pagnoux, CanVasc, Toronto, ON

During this session, the evidence about the choice of immunosuppressive therapy for the main, various forms of pulmonary vasculitis will be reviewed. This will include discussion on the role of plasma exchange for ANCA-associated vasculitis and anti-GBM disease, immunosuppression for vasculitis-related subglottic/endobronchial stenosis, and rituximab or mepolizumab in eosinophilic granulomatosis with polyangiitis.

Learning Objectives
At the end of this presentation, attendees will be able to:

  • Review the evidence about the choice and duration of immunosuppressive therapy for pulmonary vasculitis;
  • Discuss the role of plasma exchange;
  • Understand the role of immunosuppression for vasculitis-related subglottic/endobronchial stenosis; and
  • Discuss the role of mepolizumab in eosinophilic granulomatosis with polyangiitis.